Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer

  • Authors:
    • Abraham Amsterdam
    • Elias Shezen
    • Calanit Raanan
    • Letizia Schreiber
    • Diana Prus
    • Yasmin Slilat
    • Alon Ben-Arie
    • Rony Seger
  • View Affiliations

  • Published online on: June 17, 2011     https://doi.org/10.3892/ijo.2011.1090
  • Pages: 649-656
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

We examined the possibility that the localization of phosphorylated ERK1 and ERK2 (pERK1/2) can serve as a marker for the development of benign and borderline tumors as well as carcinoma of the ovary by an immunohistochemical method on ovarian paraffin sections, obtained from women aged 41-83 years. In normal tissue, 28.3% of nuclei were labeled, mainly confined to the epithelial cells at the surface of the ovary. In benign serous tumors, the label rose to 55.0%, while the intensity of the staining was weak. In contrast, in borderline serous tumors and in ovarian serous carcinoma (stage II) 52.1% and 70.3% of nuclei, respectively, were labeled with a high intensity. In mucinous benign tumors, the number of labeled nuclei was as in the control, but in addition, 49.4% of the cells demonstrated high concentration of pERK1/2 in aggregated form that was evident in the cytoplasm of the cells. In the mucinous and endometrioid ovarian carcinomas (stage II) very intensive labeling was found in 60% and 77.3% of cells, respectively. It is, therefore, suggested that since nuclear pERK1/2 can be mitogenic, it can serve as a reliable marker for the progression of ovarian cancer. Interestingly, the intense labeling of pERK1/2 was mainly confined to the peripheral areas of ovarian endometrioid carcinoma (stage II). In addition, all tumor cells in this class of cancer were positively stained with mutated p53. It seems, therefore, that immunohistochemical staining of normal and ovarian tumor cells with anti-pERK1/2 is a reliable marker for early detection of the cancer, which may assist in the early diagnosis and prognosis of this lethal disease.

Related Articles

Journal Cover

September 2011
Volume 39 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Amsterdam A, Shezen E, Raanan C, Schreiber L, Prus D, Slilat Y, Ben-Arie A and Seger R: Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. Int J Oncol 39: 649-656, 2011
APA
Amsterdam, A., Shezen, E., Raanan, C., Schreiber, L., Prus, D., Slilat, Y. ... Seger, R. (2011). Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer. International Journal of Oncology, 39, 649-656. https://doi.org/10.3892/ijo.2011.1090
MLA
Amsterdam, A., Shezen, E., Raanan, C., Schreiber, L., Prus, D., Slilat, Y., Ben-Arie, A., Seger, R."Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer". International Journal of Oncology 39.3 (2011): 649-656.
Chicago
Amsterdam, A., Shezen, E., Raanan, C., Schreiber, L., Prus, D., Slilat, Y., Ben-Arie, A., Seger, R."Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer". International Journal of Oncology 39, no. 3 (2011): 649-656. https://doi.org/10.3892/ijo.2011.1090